Previous 10 | Next 10 |
2024-03-14 17:15:01 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for SPRB on March 14, 2024 04:15PM ET. The previous analyst recommendation was Market Outperform. SPRB was trading at $0.8106 at issue of the analyst recommendation. The overall analyst...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 51.9% to $0.1549 on volume of 312,863,578 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.4% to $3.51 on volume of 229,852,079 shares SoundHound AI Inc. (SOUN) fell 3.2% to $8.37 on volu...
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB). Investors who purchased Spruce securities are encouraged to obtain additional infor...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...
2024-03-14 08:28:15 ET Losers: Spruce Biosciences ( SPRB ) -78% reports FY results Solidion Technology ( STI ) -30% climbs 10% on $3.85M private placement . Hello Group ( MOMO ) -16% after Q4 earnings release . Pagaya Technologies Ltd ( ...
2024-03-13 17:39:31 ET More on Spruce Biosciences Guggenheim starts Spruce Biosciences at buy, cites near-term catalysts Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce...
2024-03-13 17:13:12 ET More on Spruce Biosciences Guggenheim starts Spruce Biosciences at buy, cites near-term catalysts Seeking Alpha’s Quant Rating on Spruce Biosciences Read the full article on Seeking Alpha For further details see: Spruce Biosc...
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosi...
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosi...
2024-02-21 14:33:16 ET More on Spruce Biosciences Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce Biosciences Read the full article on Seeking Alpha For further...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...